Track topics on Twitter Track topics that are important to you
This is a multicenter, randomized, evaluator-blinded, comparator-controlled study. 1:1 randomization daptomycin or comparator, stratified by degree of renal impairment [creatinine clearance(CLcr) 30 - 50 mL/min and <30 mL/min] and by type of infection [bacteremia and complicated Skin and Skin Structure Infections (cSSSI)] to create 4 cohorts defined as follows:
1. Bacteremia and CLcr <30 mL/min
2. Bacteremia and CLcr 30 - 50 mL/min
3. cSSSI and CLcr <30 mL/min
4. cSSSI and CLcr 30 - 50 mL/min
Patients will be treated and evaluated for safety, microbiological and clinical efficacy in accordance with their type of infection and degree of renal impairment. Peak and trough samples will be collected to assess exposure to daptomycin for patients on Day 1 and following the 5th dose.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Complicated Skin and Skin Structure Infections
Vancomycin, Vancomycin, Daptomycin 7-14 days moderate renal impairment, Daptomycin 7 - 14 days severe renal impairment, hemodialysis, Daptomycin 7 - 14 days severe renal impairment no hemodialysis, Daptomycin 14 - 42 days, moderate renal impairment, Dapto
LA Biomedical Research Institute at Harbor UCLA Med Ctr
Published on BioPortfolio: 2014-08-27T03:14:33-0400
This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further evaluate the pharmacokinetics of intravenous (i.v.) daptomycin and the safety and efficacy of ...
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a di...
This study is to examine the safety of daptomycin in patients with End Stage Renal Disease.
The primary objective of this study is to characterise the pharmacokinetics and dose proportionality of daptomycin after single and multiple (once daily) 4mg/kg and 6 mg/kg doses of daptom...
Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant microorganisms. This antibiotic would be appropriate for use in the intensive care unit (ICU) co...
MRSA remains a major cause of severe nosocomial infections and the increased use of vancomycin and daptomycin for MRSA treatment over the last decade has led to the isolation of MRSA strains with decr...
Daptomycin-associated myopathy has been identified in 2-14% of patients, and rhabdomyolysis is a known adverse effect. Although risk factors for daptomycin-associated myopathy are poorly defined, crea...
Daptomycin is a cyclic lipopeptide effective against multidrug Gram-positive bacteria. Despite having a net negative charge, it is selective against negatively charged bacterial membranes. It has been...
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections including complicated skin and skin structure infections, right-sided infective endocarditis, bacteraem...
Daptomycin is a bactericidal antibiotic approved for the treatment of skin and soft tissue infections and right-side endocarditis. However, there is a lack of published data outlining its usefulness i...
Strains of the genus Enterococcus that are resistant to the antibiotic VANCOMYCIN. The enterococci become resistant by acquiring plasmids carrying genes for VANCOMYCIN RESISTANCE.
A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.
Nonsusceptibility of bacteria to the action of VANCOMYCIN, an inhibitor of cell wall synthesis.
Autoimmune disease characterized by subepidermal blisters and linear deposition of autoantibodies at the dermoepidermal junction. The accumulated autoantibodies are of IMMUNOGLOBULIN A and occasionally IMMUNOGLOBULIN G classes against epidermal BASEMENT MEMBRANE proteins. The dermatosis is sometimes associated with malignancies and use of certain drugs (e.g., VANCOMYCIN).
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...